Keeping balance – surfing the GLP-1 tsunami
17 December 2024In the December/January edition of LaingBuisson's HealthcareMarkets, Kirsty Withams, director of communications and content, and Jack Zeng, senior engagement manager…Ethics Symposium – AI in Medicines
12 December 2024In December, the Royal Society of Medicine was host to the Ethos Pharmaceutical Ethics & Compliance Charity Symposium, and this…Candesic provides vendor commercial due diligence to HealthNet Homecare
29 October 2024HealthNet Homecare, one of the UK’s largest clinical homecare providers, received investment from private equity firm CBPE Capital. Candesic was…Strategic issues facing pharma
8 October 2024Our pharmaceutical team has been discussing the strategic issues facing the pharmaceutical industry that in particular the number of drugs…Taking the Stage on Crete – CytoReason
30 September 2024At the end of September, CytoReason held its CytoSummit employee conference on the beautiful island of Crete. The focus was…Marc Kitten in the new Real Deals due diligence report
13 September 2024Don’t miss the inaugural Real Deals Due Diligence report, featuring insight on the unique challenges associated with healthcare due diligence…Deal or no deal?
21 March 2024Deal or no deal? In 2023, the answer was often ‘deal’! Over US$ 84 billion worth of deals were closed…Candesic examines the phenomenon of synthetic human embryos
23 October 2023Dr Leonid Shapiro, managing partner at Candesic, and Dr Joe Taylor, principal at Candesic, examine the phenomenon of synthetic human…Candesic`s Dr Joe Taylor and Dr Leonid Shapiro published in the latest PharmaTimes
20 September 2023Candesic`s Dr Joe Taylor and Dr Leonid Shapiro discuss in PharmaTimes the significant opportunities, and the challenges, in the use…
Obesity treatment and the rise of the GLP-1 agonist
17 August 2023Candesic partner Dr Michelle Tempest and Dr Bharadwaj Chada feature on the new HealthcareMarkets UK issue. Our team investigates the…
